This model has the potential to revise the therapeutic approach for cancer treatment, which suggests the use of gefitinib or JNJ alone if the R248Q mutation of p53 is detected in HGSOC patients; if the R248Q mutation of p53 is not detected, the combination of gefitinib and JNJ should be recommended. The gene discussed is TP53; the disease is cancer.